NCT04146441View on ClinicalTrials.gov

Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Carcinoma, Pancreatic Ductal
Interventions
COMBINATION_PRODUCT

SonoVue

1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only

DRUG

Chemotherapy

FOLFIRINOX Regime according to Norwegian national guidelines

Trial Locations (1)

Unknown

Department of Radiology, St Olavs Hospital, Trondheim

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

lead

St. Olavs Hospital

OTHER

NCT04146441 - Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter